Received Aug 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMXV072A | — |
they have one extra vial of the lyophilized component of Menveo, which means that a patient received only the liquid portion; they have one extra vial of the lyophilized component of Menveo, which means that a patient received only the liquid portion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 16-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMXV072A) for prophylaxis. On 29-JUL-2025, the patient received Menveo. On 29-JUL-2025, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: they have one extra vial of the lyophilized component of Menveo, which means that a patient received only the liquid portion) and inappropriate dose of vaccine administered (Verbatim: they have one extra vial of the lyophilized component of Menveo, which means that a patient received only the liquid portion). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date: 29-JUL-2025 A medical assistant mentioned that they have one extra vial of the lyophilized component of Menveo, which means that a patient received only the liquid portion, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. There were two possible patients that received only the diluent portion. For one of the patients, it was the second shot and for one of them it was the first dose. The reporter asked for recommendations on this situation. This was 1 of 2 linked cases , reported by the same reporter.; Sender's Comments: US-GSK-US2025097731:Same reporter/different patient